← Back

Accuray Incorporated

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Price · split & dividend adjusted
News & notes moving ARAY
ARAY

Accuray Withholds FY27 Guidance, Expects $15M Cost Improvement

Accuray announced it will not provide formal revenue or adjusted EBITDA guidance for fiscal 2027, instead expecting approximately $15 million of incremental annualized cost and margin improvement. The company reported fourth quarter net revenue of $100.9 million and full fiscal year 2026 revenue of $402 million, with a full-year operating loss of $26.4 million and adjusted EBITDA of $10.6 million. Management highlighted a comprehensive transaction with TCW Asset Management Company that includes conversion of $40 million of existing debt into preferred equity and a $15 million cash investment. Accuray also cited nonbinding letters of intent with Samsung HME America and RaySearch Laboratories, and a 10-year strategic collaboration with the University of Wisconsin School of Medicine and Public Health. The company plans to implement a reverse stock split at a ratio still to be determined and subject to stockholder approval.
ARAY
Seeking Alpha·7dRead more ▾
Biotech & Genomic Medicine▲2

Radiotherapy Market to Reach USD 10.68 Billion by 2031 at 6.0% CAGR

The global radiotherapy market is projected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, at a CAGR of 6.0%, according to a new report by MarketsandMarkets. Growth is driven by rising cancer incidence, increased healthcare investments, and demand for precision oncology, with rapid adoption of technologies such as proton beam therapy, adaptive radiotherapy, and AI-based treatment planning. The systems segment is expected to hold the largest share, while external beam radiotherapy dominates across technology, application, and procedure segments, and hospitals remain the leading end user. Asia Pacific is forecast to register the highest CAGR, supported by expanding oncology infrastructure and government spending in countries including China, India, and Japan. Key players include Siemens Healthineers AG, Elekta, Accuray Incorporated, IBA Worldwide, and ViewRay Technologies.
0O5H.LSE ▲ARAY ▲SHL.XETRA ▲
Biotech & Genomic Medicine ▲
GlobeNewswire·35dRead more ▾
© 2026 MarketDXAsset